Soligenix (SNGX) Receives a Buy from Maxim Group

By Ryan Adsit

Maxim Group analyst Jason McCarthy maintained a Buy rating on Soligenix (SNGXResearch Report) yesterday and set a price target of $4.00. The company’s shares closed last Monday at $1.01.

According to, McCarthy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -20.1% and a 28.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Hancock Jaffe Laboratories, and Lineage Cell Therapeutics.

Soligenix has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.39 and a one-year low of $0.65. Currently, Soligenix has an average volume of 56.55K.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SNGX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Soligenix, Inc. engages in the development and commercialization of products to treat rare disease. It operates through the following segments: BioTherapeutics and Vaccines/BioDefense.